UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☑	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended March 31, 2025
	For the fiscal year ended March 31, 2026
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _______ to _______.

Commission file number: 000-23476

GROOVE BOTANICALS INC. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Nevada		84-1168832
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

Registrant’s Principal Office

310 Fourth Avenue South, Suite 7000

Minneapolis, MN 55415

Registrant’s telephone number, including area code:

(612-315-5068)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value

Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑☒

Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☑☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☑☒ Smaller reporting company ☑☒ Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑ ☒

The aggregate market value of the registrant’s common stock, par value $0.001 per share (“Common Stock”), held by non-affiliates, computed by reference to the price at which the Common Stock was last sold as of September 30, ~~2024~~2025, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $~~709~~304,~~689~~174.

The number of shares of the registrant’s Common Stock outstanding as of June 3025, ~~2025~~2026 was 59,643,062 shares.

DOCUMENTS INCORPORATED BY REFERENCE

List hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933. The listed documents should be clearly described for identification purposes (e.g., annual report to security holders for fiscal year ended December 24, 1980).

None

TABLE OF CONTENTS

		~~Page~~	Page
PART I.
Item 1.	Business	2	3
Item 1A.	Risk Factors	4	5
Item 1B.	Unresolved Staff Comments	4	5
Item 1C	Cybersecurity	4	5
Item 2.	Properties	4	6
Item 3.	Legal Proceedings	4	6
Item 4.	Mine Safety Disclosures	4	6
PART II.
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	5	7
Item 6.	Reserved	6	9
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	6	9
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	11	12
Item 8.	Financial Statement and Supplementary Data	11	12
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	11	12
Item 9A.	Controls and Procedures	12	13
Item 9B.	Other Information	13	14
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	13	14
PART III.
Item 10.	Directors, Executive Officers and Corporate Governance	13	15
Item 11.	Executive Compensation	14	17
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	15	17
Item 13.	Certain Relationships and Related Transactions, and Director Independence	15	18
Item 14.	Principal Accounting Fees and Services	16	19
PART IV.
Item 15.	Exhibits, Financial Statement Schedules	17	20
Item 16.	Form 10-K Summary	33	34

Table of Contents

PART I

Cautionary Note Regarding Forward-Looking Statements

In addition to historical information, this Annual Report on Form 10-K of Groove Botanicals Inc. contains “forward-looking statements.” Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, future capital requirements, regulatory actions or delays and other factors that may cause actual results to be materially different from those described or anticipated by these forward-looking statements. The foregoing list of factors is not exclusive. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. All forward-looking statements are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but there can be no assurance that we will realize our expectations or that our beliefs will prove to be correct.

There may be other factors of which we are currently unaware or which we currently deem immaterial that may cause our actual results to differ materially from the forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date they are made and are expressly qualified in their entirety by the cautionary statements included in this report. Except as may be required by law, we undertake no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances occurring after the date they were made or to reflect the occurrence of unanticipated events, or otherwise.

Item 1. Business.

As used in this Annual Report on Form 10-K (this “Report”), references to the “Company,” the “registrant,” “we,” “our” or “us” refer to Groove Botanicals Inc. unless the context otherwise indicates.

Prior Operations

Organizational history

Groove Botanicals, Inc. (the “Company”), (formerly known as Avalon Oil & Gas, Inc.), was originally incorporated in Colorado on April 25, 1991 under the name Snow Runner (USA), Inc. The Company was the general partner of Snow Runner (USA) Ltd.; a Colorado limited partnership to sell proprietary snow skates under the name “Sled Dogs” which was dissolved in August 1992. In late 1993, the Company relocated its operations to Minnesota and in January 1994 changed its name to Snow Runner, Inc. In November 1994 we changed our name to the Sled Dogs Company. In May 1999, we changed our state of domicile to Nevada and our name to XDOGS.COM, Inc. On July 31, 1998, the Company split their shares One (1) for Fifty-Four (54). On August 24, 2000, the Company split their shares One (1) for Five (5) and changed our name from XDOGS.COM to XDOGS, Inc. We changed our symbol from XDGS to XDGI. On June 22, 2005, the Company changed our name from XDOGS, Inc. to Avalon Oil and Gas, Inc. We changed our symbol from XDGI to AOGS. On July 22, 2005, the Board of Directors and a majority of the Company’s shareholders approved an amendment to our Articles of Incorporation to change the Company’s name to Avalon Oil & Gas, Inc., and to increase the authorized number of shares of our common stock from 200,000,000 shares to 1,000,000,000 shares par value of $0.001. On May 15, 2007, the Company split its shares One (1) for Twenty (20). We changed our symbol from AOGS to AOGN. On June 4, 2012, the Board of Directors approved an amendment to our Articles of Incorporation to a reverse split of the issued and outstanding shares of Common Stock of the Company (“Shares”) such that each holder of Shares as of the record date of June 4, 2012 shall receive one (1) post-split Share on the effective date of June 4, 2012 for each three hundred (300) Shares owned. The reverse split was effective on July 23, 2012. On September 28, 2012, we held a special meeting of Avalon’s shareholders and approved an amendment to the Company’s Articles of Incorporation such that the Company would be authorized to issue up to 200,000,000 shares of common stock. We filed an amendment with the Nevada Secretary of State on April 10, 2013, to increase our authorized shares to 200,000,000. On July 23, 2012, the Company split their shares One (1) for Three Hundred (300). On May 14, 2018, the Company changed its name from Avalon Oil and Gas, Inc., to Groove Botanicals, Inc. We changed our symbol from AOGN to GRVE. On August 2, 2021, we filed a Form 15-12B to suspend our duty to file reports under sections 13 and 15(d) of the securities exchange act of 1934. Since inception we have operated unsuccessfully, in various different industries.

Table of Contents

Present Operations

WeThe ~~plan~~Company intends to ~~assemble~~change aour ~~portfolio~~name ~~of early-stage EV Battery Technologies developed~~ from ~~Universities~~Groove ~~in Norway~~Botanicals, Sweden and Finland, and seek grants from the State of Minnesota Department of Economic Development to find and identify corporate partners to commercialize these technologies and ultimately produce revenues for the CompanyInc. ~~The Company does not currently own any patents or technologies related to the EV battery industry~~, ~~and the process~~ to ~~acquire~~Nordmark ~~patents and technologies can be costly~~Technologies, ~~and as such~~Inc., ~~the Company is not guaranteed~~ to ~~acquire~~better ~~any~~describe ~~such~~our ~~patents~~corporate focus.

~~Management~~The ~~believes~~Company ~~that~~is ~~the~~an early-stage company. We intend to identify and evaluate early-stage intellectual property and applied technologies ~~available~~that inmay originate from, or be developed within, the ~~specialized~~ ~~energy~~research ~~industry~~ecosystems ~~present~~of aNorwegian ~~stable~~universities, ~~business~~university ~~model~~hospitals, ~~with~~applied ~~high~~research ~~growth~~institutions, ~~potential~~and related technology-transfer or innovation organizations, and weto ~~are~~assess ~~actively~~whether ~~working~~selected ~~towards~~technologies anmay ~~impactful acquisition~~be suitable for licensing, further development, or commercialization in ~~this~~North ~~space~~America through licensing, strategic relationships, commercial partnerships, customer arrangements, or other commercial structures, if available.

We have selected an initial geographic focus on Norway as we believe a concentrated review of a defined research ecosystem may allow us to evaluate opportunities more efficiently. We believe certain Norwegian institutions are active in selected applied-technology sectors that may be relevant to North American markets, which may include energy and offshore technology, maritime and ocean industries, aquaculture, carbon capture, health sciences, medical technology, and other applied industrial and digital technologies. By way of illustration and not limitation, the types of institutions whose research we may consider include the University of Oslo, Oslo University Hospital and its associated technology-transfer organization, SINTEF, the Norwegian University of Science and Technology, and the University of Bergen, among others.

We are in an early stage of development, we have not entered into any licensing agreements or formal arrangements with any of these institutions or any other Norwegian research organization or any university, research institution, or technology transfer organization to date. Nor have we identified or have any specific technology or intellectual property rights under contract, and we do not have proprietary or exclusive access to any technology pipeline. There can be no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.

As the Company continues its business development and asset acquisitions, the Company anticipates our capital needs to be between $500,000 and $5,000,000 (varying based on growth strategies).

Principal Products

We do not currently have any products, technologies, or intellectual property rights. WeOur current activities are ~~working~~focused toon ~~assemble a~~identifying ~~portfolio~~and ofevaluating potential licensing, development, or commercialization opportunities involving early-stage EVtechnologies ~~Battery~~and ~~Technologies~~applied intellectual property that originate from universities and research institutions in Norway.

Marketing, Sales and Customer Service

We currently are not undertaking any marketing or sales activities.

Competition

~~Entering~~The ~~the~~market ~~Green~~for ~~Energy~~identifying, ~~Market~~licensing, developing, and commercializing early-stage technologies and intellectual property is highly competitive. ~~and there~~We ~~are~~may ~~many~~compete ~~large~~with established companies, ~~focusing~~universities, onresearch ~~the~~institutions, ~~industry.~~venture ~~Several~~funds, ~~small~~technology-transfer ~~companies~~organizations, ~~have~~strategic ~~entered~~investors, ~~the~~and ~~space~~other ~~and~~commercialization ~~caused~~platforms itthat tomay ~~become~~have ~~fragmented and~~greater ~~the~~capital, ~~barrier~~technical ~~for~~expertise, ~~entry~~institutional torelationships, ~~the~~and ~~market~~operating isresources ~~more~~than ~~complicated~~we do.

2 4 Table of Contents

Intellectual Property

The Company does not currently own, license, or control any ~~patents~~early-stage technologies or ~~technologies related~~intellectual toproperty ~~the~~rights EVoriginating ~~battery~~from ~~industry~~Norwegian universities, ~~and~~university ~~the~~hospitals, ~~process~~applied toresearch ~~acquire~~institutions, ~~patents~~or ~~and~~related ~~technologies~~innovation organizations. There can be ~~costly,~~no ~~and~~assurance asthat ~~such,~~we ~~the~~will ~~Company~~identify issuitable ~~not guaranteed~~technologies, toobtain ~~acquire~~intellectual ~~any~~property ~~such patents.~~rights

~~Government~~on ~~and~~acceptable ~~Industry~~terms, ~~Regulation~~or successfully protect, develop, or commercialize any intellectual property.

The Biden-Harris Administration and 117th Congress have passed critical legislation that will establish U.S. leadership in electric transportation and maintain our global competitiveness in the automotive industry. The Infrastructure Investment and Jobs Act (https://www.congress.gov/bill/117th-congress/house-bill/3684), and the Inflation Reduction Act (https://electrificationcoalition.org/work/federal-ev-policy/inflation-reduction-act/) are historic acts that invest hundreds of millions into the EV sector. They will bolster U.S. manufacturing and supply chains to support the transition for both the light-duty and medium- and heavy-duty sectors.

Beginning January 1, 2023, the Clean Vehicle Credit (CVC) provisions removed the manufacturer sales caps for vehicles sold after January 1, 2023, expanded the scope of eligible vehicles to include both EVs and FCEVs, and required that the battery powering the vehicle has a capacity of at least seven kilowatt-hours (kWh).

The National Highway Traffic Safety Administration (NHTSA) established the Battery Safety Initiative for Electric Vehicles (Initiative) to coordinate research and other activities relating to electric vehicle (EV) battery safety. The Initiative is responsible for:

• Collecting and analyzing data related to EV batteries; • Examining field incidents and conducting battery safety investigations from EV crash and non-crash events; • Researching and evaluating EV battery health, battery management systems and cybersecurity, and high-voltage battery charging failures and effects; and, • Investigating safety-related battery defects.

The NHTSA Initiative also participates in the development of Global Technical Regulation (GTR) No. 20 for EV Safety(PDF) (https://unece.org/fileadmin/DAM/trans/main/wp29/wp29wgs/wp29gen/wp29registry/ECE-TRANS-180a20e.pdf) which includes battery fire safety. For more information, see the NHTSA’s Initiative (https://www.nhtsa.gov/battery-safety-initiative) website.

The Secretaries of Transportation and Energy jointly established an EVWG to make recommendations regarding the development, adoption, and integration of light-, medium-, and heavy-duty electric vehicles (EVs) into the transportation and energy system of the United States. The EVWG is comprised of 25 members from federal agencies, the automotive industry, the energy industry, state and local governments, labor organizations, and the property development industry. The EVWG will produce three reports describing the status of EV adoption, including barriers and opportunities to scale up EV adoption, and recommendations for EV issues including EV charging station needs, manufacturing and battery costs, EV adoption for low- and moderate-income individuals and underserved communities, and EV charging station permitting and regulatory issues. The first report must be submitted within 18 months of the EVWG establishment, and the second and third reports each two years thereafter. Based on the EVWG reports, the Secretaries of Transportation and Energy must jointly develop, maintain, and update an EV strategy that includes how the federal, state, and local governments, and industry can establish quantitative transportation electrification targets, overcome barriers, provide public EV education and awareness, identify areas of opportunity in research and development to lower EV cost and increase performance, and expand EV charging station deployment. The Secretaries and the Working Group will use existing federal resources such as the Alternative Fuels Data Center (https://afdc.energy.gov/), the Energy Efficient Mobility Systems (https://www.energy.gov/eere/vehicles/energy-efficient-mobility-systems/) program, and the Clean Cities and Communities Coalition Network (https://cleancities.energy.gov). The EVWG was established on June 8, 2022, and will terminate upon the submission of the third and final report. For more information, see the EVWG (https://driveelectric.gov/ev-working-group/) website.

(Reference Public Law 117-58 (https://www.congress.gov/public-laws/117th-congress) and 23 U.S. Code 151 (https://www.govinfo.gov/))

New Policies which may impact our business plan:

“Donald Trump’s return to the presidency has brought sweeping changes to the electric vehicle (EV) and battery sectors. Among the most consequential moves, Trump revoked a 2021 executive order targeting 50% EV sales by 2030, a change certain to disrupt automakers’ strategies. The 2021 order had been instrumental in shaping automakers’ strategies and fostering EV adoption in the U.S. While the target was nonbinding, it was supported by major automakers, who now face significant uncertainties.

Trump’s administration has also frozen $5 billion allocated for EV charging stations, a move that will potentially slow the expansion of critical infrastructure needed to support widespread EV adoption. The administration also aims to eliminate state emissions waivers, such as California’s, which set stricter rules for phasing out gasoline-powered vehicles by 2035. If successful, this could stall progress in the transition to EVs in multiple states, affecting automakers who have invested heavily in EV development in response to these

regulations. Instead, Trump’s policies favor reallocating funds to bolster domestic battery manufacturing for “national defense supply chains.”

The Environmental Protection Agency (EPA) has been directed to reevaluate rules requiring automakers to increase EV production to meet stricter emissions controls by 2032. The administration’s swift policy reversal has already led to market volatility and raised concerns about the future of U.S. EV and battery initiatives.

Financial markets react to policy uncertainty

The financial impact of these changes has been immediate. Shares in Asian automakers and battery makers dropped following Trump’s announcements, highlighting the global ripple effects of U.S. policy shifts. South Korean battery manufacturers, such as LG Energy Solution and SK Innovation, experienced declines of 4.3% and 3.7%, respectively, as reported by Reuters. Japanese automakers also faced challenges, with Mazda Motor and Honda Motor shares falling 2% and 0.3%.

Despite these setbacks, Chinese EV manufacturers’ shares rose after Trump refrained from targeting Beijing in his inauguration speech, reflecting the intricate dynamics of global EV competition. Takahide Kiuchi, chief economist at Nomura Research Institute, told Reuters that additional tariffs and policy changes could worsen export conditions for Asian countries reliant on U.S. markets.

Impact on EV incentives and US manufacturers

Trump’s rollback of EV mandates includes a push to reconsider the popular $7,500 federal tax credit for EV purchases. Narrowing eligibility criteria for this tax credit could potentially reduce the number of qualifying vehicles, influencing consumer behavior by raising the effective cost of EVs. Automakers may need to adjust their strategies to account for this shift. While fully repealing the tax credit would require Congressional action, Trump’s administration may narrow eligibility criteria, reducing the number of vehicles that qualify for incentives. This could disproportionately impact companies like Tesla, General Motors, and Ford, which have invested heavily in U.S.-based battery factories to benefit from previous subsidies.

Automakers with Mexican manufacturing operations are also under pressure. Trump has indicated potential 25% tariffs on vehicles imported from Canada and Mexico, starting as early as February. These tariffs would significantly affect companies like Honda and Mazda, which rely on Mexican plants to supply the U.S. market. Nissan, which exports approximately 300,000 vehicles annually from Mexico to the U.S., also faces heightened risks.

Broader industry repercussions

The EV industry’s growth has been closely tied to stable incentives and policies. According to PwC, U.S. EV adoption was on track to reach 27 million vehicles by 2030, driven by government support. Trump’s abrupt policy reversals could stall this momentum, affecting both domestic and global manufacturers. The Financial Times noted that regulatory overhauls, while not immediate, could have a chilling effect on the market as automakers and investors adapt to new uncertainties.

Trump’s decision to resume issuing export permits for liquefied natural gas (LNG) projects and his emphasis on energy independence signal a broader shift away from clean energy initiatives.

Challenges ahead for automakers and battery makers

As the U.S. EV market adjusts to these sweeping changes, automakers and battery manufacturers must navigate an increasingly complex landscape. Legal challenges to Trump’s policies are likely, but the administration’s swift actions have already created significant market disruptions. For now, the industry faces an uncertain future, with stakeholders bracing for the long-term implications of these policy shifts.”

Credit: “Battery Technology”– Author Michael C. Anderson, Editor-in-Chief, Battery Technology, Informa Markets – Engineering, Copyright © 2025 All rights reserved. Informa Markets, a trading division of Informa PLC.

Employees

We have one full time employee, our President, Kent Rodriguez and a part time administrative assistant. The Board retains consultants and advisors on as needed basis. They are compensated with cash and also with the issuance of the Company’s common stock.

Research and Development

We did not have any research and development costs during fiscal ~~2025~~2026 and ~~2024~~2025.

Recent Developments

Other Information

None

Item 1A. Risk Factors

Smaller reporting companies are not required to provide the information required by this item.

For risks relating to our operations, see “Risk Factors” contained in our Form 10-12g/A filed with the SEC on November 6, 2023

Item 1B. Unresolved Staff Comments

None

Item 1C. Cybersecurity

We recognize the importance of developing, implementing, and maintaining robust cybersecurity measures to protect our information systems and protect the confidentiality, integrity, and availability of our data. Presently our information systems are limited to databases maintained by third parties. As a result, we have limited policies and procedures to assess, identify, and manage material risk from cybersecurity threats. We assess risks from cybersecurity threats against our third-party information systems that may result in adverse effects on our information systems or any information residing therein. We conduct periodic and ad-hoc assessments to identify cybersecurity threats. Presently we do not believe there are any material threats to our systems.

Following these risk assessments, if needed, we evaluate whether and/or how to re-design, implement, and maintain reasonable safeguards to mitigate identified risks and reasonably address any identified gaps in existing safeguards. We do not yet have an IT manager given our limited exposure to risks, and therefore the review of our limited systems is undertaken by our President to manage the risk assessment and mitigation process. When applicable to our corporate structure and when we believe exposure to risks within our systems exceeds the current limited levels of exposure, we will monitor and test our safeguards and train our employees on the implementation of such safeguards, in collaboration with human resources, IT, and management, as available. We aim to promote a company-wide culture of cybersecurity risk management as we grow in size.

Table of Contents

Risks from Cybersecurity Threats

As of the date of this report, we are not aware of any cybersecurity incidents, that have had a materially adverse effect on our operations, business, results of operations, or financial condition.

Governance

Our board of directors is responsible for monitoring and assessing strategic risk exposure. Our board of directors administers its cybersecurity risk oversight function directly as a whole. Our President is responsible for assessing and managing our material risks from cybersecurity threats and conducts this assessment on a regular basis, or at least once per year.

Item 2. Properties

Our corporate office is located at 310 Fourth Avenue South, Suite ~~700~~7000, Minneapolis, MN 55415. This office space is rented from an unaffiliated third party on a month-to-month basis under terms of a verbal agreement for a monthly rental of $1,200.

Item 3. Legal Proceedings

There are no pending legal proceedings to which we are a party or in which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5% of any class of our voting securities, or security holder is a party adverse to us or has a material interest adverse to us.

Item 4. Mine Safety Disclosures

Not applicable

5 6 Table of Contents

PART II

a) Market Information

Our common stock is currently quoted on OTCMarkets OTCID under the symbol GRVE. For the periods indicated, the following table sets forth the high and low bid prices per share of common stock. The below prices represent inter-dealer quotations without retail markup, markdown, or commission and may not necessarily represent actual transactions.

Period	~~High~~	~~Low~~High		Low
Quarter ended March 31, 2025	0.0163	0.006
Quarter ended March 31, 2026			0.0700		0.0071
Quarter ended December 31, 2024	0.0163	0.0012
Quarter ended December 31, 2025			0.0190		0.0053
Quarter ended September 30, 2024	0.02	0.0053
Quarter ended September 30, 2025			0.0083		0.0032
Quarter ended June 30, 2024	0.050	0.005
Quarter ended June 30, 2025			0.0060		0.0028
Quarter ended March 31, 2024	.050	.020
Quarter ended March 31, 2025			0.0163		0.006
Quarter ended December 31, 2023	.127	.023
Quarter ended December 31, 2024			0.0163		0.0012
Quarter ended September 30, 2023	.177	.035
Quarter ended September 30, 2024			0.02		0.0053
Quarter ended June 30, 2023	.298	.043
Quarter ended June 30, 2024			0.050		0.005

b) Holders

On March 31, ~~2025~~2026, there are approximately ~~720~~709 holders of record of our common stock.

Table of Contents

c) Dividends

Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. Holders of Series A Stock are entitled to receive dividends on shares of Series A Preferred equal (on an as- converted to common stock basis) to and in the same form as dividends actually paid on our common stock.

Series A Preferred Stock holds designations of cash dividends at the rate of 8% of the amount per share of Series A Preferred Stock per annum in the form of “Preferred Dividends”, voting rights on an as-converted to Common Stock basis, liquidation preferences, and conversion rights in which each share of Series A Preferred Stock shall, upon conversion, represent 0.51% of the then “Fully-Diluted Shares Outstanding” of the Company. On January 12, 2018, our Board of Directors agreed to amend Designation of the Series A Convertible Preferred Stock be amended by changing the ratio for conversion, in Article IV, subparagraph (a), from 0.4% to 0.51% so that upon conversion the number of shares of common stock to be exchanged shall equal 51% of then issued and outstanding common stock. In addition, on January 12, 2018, the Company and the Series A Holder agreed to forgive all accrued interest to date on the Series A, and to pause any accruals until April 1, 2023. The Series A Convertible Preferred Stock carries liquidating preference, over all other classes of stock, equal to the amount paid for the stock plus any unpaid dividends. Currently the value of the liquidation preference is $500,000, the amount of debt that the related party converted into the preferred stock. If this Preferred Stock were to be redeemed by the holder, it would result in an aggregate of the $500,000 liquidation preference, on a per share basis, this would equal $5,000 per share. The Company and Series A Preferred Holder agreed to forgive all accrued interest and arrearages in preferred share dividends of Series A Preferred Stock through March 31, 2023. Dividends began to accrue on the Series A Preferred Stock as of April 1, 2023.

During the fiscal year ended March 31, ~~2025~~2026, and ~~2024~~2025, the holder of the Series A preferred shares accrued $40,000 in preferred dividends from the Series A preferred shares. A total of $80120,000 and $4080,000 in dividends was outstanding at March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively. Mr. Kent Rodriguez, the Company’s CEO, is the sole holder of the Company’s Series A Preferred shares.

Series B Preferred Stock holds designations of being ranked junior to the Series A Preferred Stock, cash dividends at the rate of 9% of the amount per share of Series B Preferred Stock per annum in the form of “Preferred Dividends”, a dividend received deduction for federal income tax purposes, liquidation preferences ranked junior to the Series A Preferred Stock, redemption of the Series B Preferred Stock by the Company at 105% of the Stated Value, plus accrued and unpaid Dividends, if prior to the two year anniversary of the Issuance Date, or at 100% of the State Value, plus accrued and unpaid Dividends, if on or after the two year anniversary of the Issuance Date, no voting rights, and right to notice of certain corporate action. All accrued dividends on the Series B have been settled through March 31, 2023, and none currently remains outstanding. Dividends began to accrue on the Series B Preferred Stock as of April 1, 2023.

During the fiscal year ended March 31, ~~2025~~2026, and ~~2024~~2025, the holders of the Series B preferred shares accrued $178,~~468~~470, in preferred dividends from the Series B preferred shares. A total of $~~356~~535,~~940~~ 410 and $~~178~~356,~~470~~940 in Preferred B dividends was outstanding at March 31, ~~2025,~~2026 and March 31, ~~2024~~2025, respectively, including dividends accrued for the benefit of Mr. Kent Rodriguez, CEO, of $33,195 for each respective year ended March 31, 2026 and 2025.

d) Securities Authorized for Issuance Under Equity Compensation Plans

No equity compensation plan or agreements under which our common stock is authorized for issuance ~~has~~have been adopted during the fiscal years ended March 31, ~~2025~~2026 and ~~2024~~2025. We have no equity compensation plans at this time.

e) Recent Sales of Unregistered Securities -

OnThere ~~April~~were 8,no ~~2022, the Company issued 500,000~~ shares of common stock, ~~250,000~~issued ~~each~~during tothe ~~two~~fiscal ~~separate~~year ~~parties,~~ended ~~of which it had previously committed in exchange for $10,000 it had received, $5,000 from each party, received on~~ March 2231, ~~2022~~2026.

On April 8, 2022, the Company issued 2,500,000 shares of common stock, of which it had previously committed in exchange for $40,000 it had received on March 23, 2022.

On October 4, 2022, the Company issued 150,000 shares of common stock in exchange for $3,000 received.

On October 4, 2022, the Company issued 250,000 shares of common stock in exchange for $4,963 received.

On December 1, 2022, the Company issued 500,000 shares of common stock in exchange for consulting services. These shares were issued with an approximate value of $0.0598 per share, based on the fair market value as of their date of issuance.

On December 1, 2022, the Company issued 1,500,000 shares of common stock to three different parties in the amounts of 1,000,000, 250,000, and 250,000, in exchange for $29,970 received.

On December 1, 2022, the Company issued 250,000 shares of common stock in exchange for $4,970 received.

On January 31, 2023, the Company issued 2,750,000 shares of common stock for conversion of debt.

On February 21, 2023, the Company issued 50,000 shares of common stock for website and social media services. These shares were issued with a value of $0.08 per share.

On April 15, 2023, the Company issued 1,000,000 shares of common stock in exchange for consulting services. These shares were valued at $0.0783 per shares per their corresponding consulting agreement.

On December 20, 2023, the Company issued 1,000,000 shares of common stock in exchange for $20,000 in cash proceeds.

There were no further shares of common stock issued from December 20, 2023 to March 31, 2025.

f) Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

Table of Contents

Item 6. Reserved

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Annual Report on Form 10-K contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled “Risk Factors” in our registration statement on Form 10-12G/A, as filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2023, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.

7 The management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated audited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

The ~~management’s~~Company ~~discussion~~relies ~~and~~primarily ~~analysis~~on ofits ~~our~~current ~~financial condition~~sole officer and ~~results~~director, ofKent ~~operations~~Rodriguez, ~~are~~to ~~based~~manage ~~upon~~its ~~our~~day-to-day ~~consolidated~~business ~~unaudited financial~~and ~~statements,~~has ~~which~~outsourced ~~have~~professional ~~been~~services ~~prepared~~to inthird ~~accordance with~~parties ~~accounting principles generally accepted~~ in ~~the~~an ~~United~~effort ~~States~~to ofmaintain ~~America~~lower ~~(“GAAP”)~~operational costs.

The Company relies primarily on its current sole officer and director, Kent Rodriguez to manage its day-to-day business and has outsourced professional services to third parties in an effort to maintain lower operational costs.

Mr. Rodriguez, as the holder of the Company’s issued and outstanding shares of the Company’s Series A Preferred Stock, holds 51% of the voting rights of the Company. He will be able to influence the outcome of all corporate actions requiring the approval of our stockholders.

Results of Operations

Revenue

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.

Operating Expenses

For the fiscal years ended March 31, ~~2025~~2026, and ~~2024~~2025 we had the following operating expenses:

	For the Year ended March 31,
	2025		2024
	2026		2025
Operating expenses:
Selling, General and Administrative Expenses	$	73,~~087~~774	$	7370,~~743~~087
Rent		1514,~~435~~400		1815,~~576~~435
Legal and Professional Expenses		4243,~~312~~743		9542,~~962~~312
Consulting Expense		—8,000		783,~~300~~000
Total operating expenses	$	~~130~~139,~~834~~917	$	~~266~~130,~~581~~834

~~Total~~9 ~~operating~~Table ~~expenses for the fiscal year ended March 31, 2025, were $130,834 compared to total operating expenses~~ of $266,581 for the fiscal year ended March 31, 2024. The decrease in operating expenses during the fiscal year ended March 31, 2025, is mainly due to a reduction in consulting expenses from $78,300 (March 31, 2024) to $Nil (March 31, 2025). Consulting expenses recorded in the year ended March 31, 2024 were the result of a consulting agreement with an independent third party settled by shares of common stock valued at $78,300 which terminated in the period ended March 31, 2024. The Company recorded a slight reduction in general and administrative expenses from $73,743 in the fiscal year ended March 31, 2024, to $73,087 for the fiscal year ended March 31, 2025. Rent remained relatively constant for the fiscal years ended March 31, 2025, and 2024, with a slight decrease of $3,141 in the fiscal year ended March 31, 2025, due to the cancellation of previously rented storage space during the year ended March 31, 2025. Professional fees decreased from $95,962 (March 31, 2024) to $42,312 for the fiscal year ended March 31, 2025 substantially due to a reduction in audit costs and professional fees in the current fiscal year. Increased professional fees in fiscal 2024 were the result of filing a Form 10 with the SEC and the associated requirement for additional legal and accounting fees associated with these filings. Contents

~~Other~~Total ~~Income~~operating expenses for the fiscal year ended March 31, 2026, were $139,917 compared to total operating expenses of $130,834 for the fiscal year ended March 31, 2025. The increase in operating expenses during the fiscal year ended March 31, 2026, is mainly due to an increase in consulting expenses from $3,000 (~~Expense~~March 31, 2025) to $8,000 (March 31, 2026). Consulting expenses recorded in the year ended March 31, 2026 and 2025 were the result of consulting fees charged by an independent third party for the preparation of our regulatory filings. The Company recorded a slight increase in general and administrative expenses from $70,087 in the fiscal year ended March 31, 2025, to $73,774 for the fiscal year ended March 31, 2026. This increase is related mainly to a reclassification of expenses in the amount of $3,000 over the fiscal year ended March 31, 2025. Rent remained relatively constant for the fiscal years ended March 31, 2026, and 2025, with a slight decrease of $1,035 in the fiscal year ended March 31, 2026, due to the cancellation of previously rented storage space during the year ended March 31, 2025. Professional fees remained relative constant at $43,743 for the fiscal year ended March 31, 2026 and $42,312 for the fiscal year ended March 31, 2025.

	March 31, 2024		March 31, 2023
Other Income (Expense)
Amortization of Debt Discount	$	—	$	—
Change in Derivative Liability		—		—
Gain on Settlement of Debt		—		71,242
Interest Income (Expense)		—		(6,750	)
Miscellaneous Other Income (Expense)		—		—
Total Other Income (Expense)	$	—	$	64,492

Other income in the fiscal year ended March 31, 2025, was nil, as compared to other income in the fiscal year ended March 31, 2025, of $64,492, comprised of a gain on settlement of certain debt by the issuance of stock valued at $71,242, offset by interest expense of $6,750 with no comparable expense in the fiscal year ended March 31, 2025.

Net Loss

Net (loss)	$	(130,834	)	$	(202,089	)
	March 31, 2026			March 31, 2025
Net (loss)	$	(139,917	)	$	(130,834	)
Dividend on Preferred Stock		(218,470	)		(218,470	)
Net (loss) attributable to common shareholders	$	(~~349~~358,~~304~~387	)	$	(~~420~~349,~~559~~304	)
Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)

We reported a net loss of $~~130~~139,~~834~~917 for the fiscal year ended March 31, ~~2025~~2026, as compared to a net loss of $~~202~~130,~~089~~834 in the fiscal year ended March 31, ~~2024~~2025.

Dividends on Preferred Stock

Dividends on Preferred Stock remained constant at $218,470 for each of the fiscal years ended March 31, ~~2025~~2026, and ~~2024~~2025. These dividends on preferred stock are required subject to the designation of the preferred stock and contribute to the net loss attributable to our common stockholders.

Operating Activities

The following table summarizes our operating activities for the period presented:

	For the Year ended March 31,
	2025			2024
	2026			2025
Net cash used by operating activities	$	(~~107~~91,~~422~~668	)	$	(86107,~~835~~422	)
Net cash provided from (used by) investing activities		—-			—
Net cash provided from financing activities		~~107~~91,~~776~~128			83107,~~957~~776
Net Change in Cash	$	~~354~~(540	)	$	~~(2,878~~354	)

Cash Used in Operating Activities

Cash used in operating activities for the year ended March 31, ~~2025~~2026 was $~~107~~91,~~422~~668 as compared to $86107,~~835~~422 used in the year ended March 31, ~~2024~~2025.

Net cash used in operating activities for the fiscal year ended March 31, 2026, was primarily the result of a net loss of $91,668, offset by non-cash items including accrued payroll of $48,000, an increase in prepaid expenses of $452 and a increase in accounts payable and accrued liabilities of $701.

Table of Contents

Net cash used in operating activities for the fiscal year ended March 31, 2025, was primarily the result of a net loss of $130,834, offset by non-cash items including accrued payroll of $48,000, an increase in prepaid expenses of $2,024 and a decrease in accounts payable and accrued liabilities of $22,564.

Net cash used in operating activities for the fiscal year ended March 31, 2024, was primarily the result of a net loss of $202,089 offset by a gain on settlement of debt of $71,242, and non-cash items, including stock issued for outside services of $78,300, accrued interest of $6,750 and accrued payroll of $48,000. Changes in working capital include an increase to accounts payable and accrued liabilities of $53,418 and a decrease in prepaid expenses of $28.

Cash Provided by Investing Activities

There was no cash provided by investing activities for the years ended March 31, ~~2025~~2026 and 2025.

Cash Provided by Financing Activities

	March 31, 2024			March 31, 2023
	March 31, 2026			March 31, 2025
Cash Flow From Financing Activities
Funds received from Related Party		~~107~~95,~~776~~320			~~104~~107,~~915~~776
Funds distributed to Related Party		—(4,192	)		~~(958~~—	)
Repayment of Outstanding Convertible Debt		—			(40,000	)
Net Cash From Financing Activities		91,128			107,776
Repayment of Outstanding Contingent Liability		—			—
Funds received for Issuance of Common Stock		—			20,000
Net Cash From Financing Activities		107,776			83,957

9 During the fiscal year ended March 31, 2026 financing activities consisted solely of related party advances in the amount of $95,320 offset by funds distributed to a related party to pay advances.

During the year ended March 31, 2024, financing activities provided cash of $124,915 as a result of related party advances of $104,915 and funds received for the issuance of common stock of $20,000 for ongoing operations, offset by funds paid to a related party of $958 and repayments of outstanding convertible debt of $40,000 for net cash from financing activities of $83,957.

During the fiscal year ended March 31, 2025 financing activities consisted solely of related party advances in the amount of $107,776.

Liquidity and Capital Resources

We are in need of additional cash resources to maintain our operations. As of March 31, ~~2025~~2026, we had cash of $21,~~042~~502 and prepaid expenses of $2,~~478~~930. We are in the early stage of development and have experienced net losses to date and have not generated revenue from operations, which raises substantial doubt about our ability to continue as a going concern. There are a number of conditions that we must satisfy before we will be able to ~~acquire~~identify, evaluate, license, ~~and~~develop, ~~acquire~~or ~~products and~~commercialize any technologies or intellectual property, ~~not~~including ~~the~~sourcing ~~least~~suitable ofopportunities, ~~which~~negotiating isacceptable ~~negotiating~~terms, ~~and~~obtaining any required financing, ~~any~~and ~~acquisitions.~~establishing Weappropriate ~~are~~strategic inor ~~the~~commercial ~~process~~relationships. ofWe ~~identifying and~~have ~~establishing~~not ~~strategic~~yet ~~partners~~identified ~~and~~any ~~technologies~~specific intechnology ~~order~~or tointellectual ~~establish~~property arights ~~market~~under contract, and ~~generate~~we ~~commercial~~have ~~orders~~not byestablished ~~customers~~any ~~and~~market, ~~licensing which~~customer ~~will~~orders, ~~include~~licensing ~~effective~~revenue, ~~marketing~~or ~~and~~commercial sales capabilities ~~for~~with respect to any ~~products~~such technologies or intellectual property. We do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue and expect to incur increasing operating expenses. We will require substantial additional funds for operations, the service of debt and to fund our business objectives. There can be no assurance that financing, whether debt or equity, will always be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms favorable to us. If additional funds are raised by the issuance of equity securities, such as through the issuance and exercise of warrants, then existing stockholders will experience dilution of their ownership interest. If additional funds are raised by the issuance of debt or other equity instruments, we may be subject to certain limitations in our operations, and issuance of such securities may have rights senior to those of the then existing stockholders. We currently have no agreements, arrangements or understandings with any person or entity to obtain funds through bank loans, lines of credit or any other sources.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $~~130~~139,~~834~~917 and $~~202~~130,~~089~~834 before dividends payable on preferred stock for the fiscal years ended March 31, ~~2025~~2026 and ~~2024~~2025, respectively. The Company’s accumulated deficit was $35,~~196~~554,~~581~~968 and $3435,~~847~~196,~~277~~581 as of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to 1) ~~focus~~focusing on our new business model and 2) raising equity or debt financing. Our auditors express substantial doubt about our ability to continue as a going concern.

Table of Contents

Off Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in the Notes to our Financial Statements.

Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.

Item 7A. Quantitative and Qualitative Disclosures about Market Risks.

Disclosure in response to this Item is not required for a smaller reporting company.

Item 8. Financial Statements and Supplementary Data.

The financial statements required by this Item 8 are included in this Annual Report beginning on page F-1.

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure.

On May 813, ~~2024~~2026, ~~the~~Madhava ~~Board~~Rao, ofChartered ~~Directors~~Accountant ~~of Groove Botanicals Inc.~~ (~~the~~PCAOB ~~“Company”~~ID 06662) ~~approved the dismissal of BF Borgers CPA PC~~ (“BFMadhava ~~Borgers~~Rao”) resigned as the ~~Company’s~~ independent registered public accounting firm. Onof ~~May~~Groove 3Botanicals, ~~2024~~Inc., ~~the~~a ~~Securities~~Nevada ~~and~~corporation ~~Exchange Commission~~ (the “~~SEC~~Company”), ~~announced~~effective ~~that~~immediately. itMadhava ~~had settled~~Rao ~~charges~~did ~~against~~not BFprovide ~~Borgers~~a ~~that~~reason itfor ~~failed~~his toresignation. ~~conduct~~On ~~audits in accordance with~~ the ~~standards~~same ofdate, the ~~Public~~ Company’s ~~Accounting Oversight~~ Board ~~(the~~of ~~“PCAOB”).~~Directors, Aswhich ~~part~~also ofserves as the ~~settlement,~~Company’s BFaudit ~~Borgers~~committee, ~~agreed~~accepted toMadhava aRao’s ~~permanent~~resignation. ~~ban~~The onCompany ~~appearing~~has orauthorized ~~practicing before~~Madhava ~~the~~Rao ~~SEC~~to ~~(the~~respond ~~“Ban”).~~fully Asto athe ~~result~~inquiries of BFGSKCA ~~Borgers’~~& ~~settlement~~Associates ~~with the SEC~~(“GSKCA”), the ~~Company~~successor ~~dismissed BF Borgers as its independent accountant~~auditors.

~~The~~Madhava Rao’s reports ~~of BF Borgers~~ on the Company’s ~~consolidated~~ financial statements for the fiscal years ended March 31, ~~2023~~2025 and ~~2022~~March 31, 2024 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, ~~other~~except ~~than~~that each such report contained an explanatory paragraph ~~relating to~~regarding substantial doubt about the Company’s ability to continue as a going concern. ~~The Company had not yet engaged a report from BF Borgers for our fiscal year ended March 31, 2024 as of the date of the Ban.~~

During the Company’s two most recent fiscal years ended March 31, ~~2023~~2025 and ~~2022~~March 31, 2024, and ~~through~~ the ~~date~~subsequent ofinterim ~~termination,~~period through May 813, ~~2024,~~2026: (i) there were no “disagreements” ~~with~~between BFthe ~~Borgers~~Company and Madhava Rao on any ~~matter~~matters of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of BF ~~Borgers~~Madhava Rao, would have caused BFreference ~~Borgers~~ to ~~make~~the ~~reference~~subject ~~thereto~~matter inof ~~its reports on~~ the ~~consolidated~~disagreements ~~financial~~in ~~statement~~connection ~~for~~with ~~such~~his ~~years. During~~reports on the ~~fiscal~~Company’s ~~years~~financial ~~ended~~statements; ~~March 31, 2023~~ and ~~2022,~~(ii) ~~and through May 8, 2024,~~ there ~~have~~were ~~been~~ no “reportable events” (as ~~defined~~ described in Item 304(a)(1)(~~iv) and Item 304(a)(1)(~~v) of ~~Registration~~Regulation S-K)~~, except for the identified material weaknesses in its internal control over financial reporting as disclosed in the Company’s Annual Report~~.

~~The~~12 ~~U.S.~~Table ~~Securities and Exchange Commission (the “SEC”) has advised that, in lieu~~ of obtaining a letter from BF Borgers stating whether or not it agrees with the statements herein, the Company may indicate that BF Borgers is not currently permitted to appear or practice before the SEC for reasons described in the SEC’s Order Instituting Public Administrative and Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Sections 4C and 21C of the Securities Exchange Act of 1934 and Rule 102(e) of the Commission’s Rules of Practice, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order, dated May 3, 2024.Contents

On ~~June~~May 13, ~~2024~~2026, concurrently with its acceptance of Madhava Rao’s resignation, the Board of Directors ~~approved~~ of the ~~appointment~~Company of(acting ~~M.S.~~in ~~Madhava~~its ~~Rao,~~capacity ~~Chartered~~as ~~Accountant~~the Company’s audit committee) approved the engagement of GSKCA & Associates (“~~Rao~~GSKCA”) as the Company'’s new independent registered public accounting firm, effective immediately,. During tothe ~~perform~~Company’s ~~independent~~two ~~review~~most ~~and~~recent ~~audit services for the~~ fiscal years ~~ending~~ended March 31, ~~2024~~2025 and ~~2023.~~ ~~During the fiscal years ended~~ March 31, 2024, and ~~2023~~the ~~and~~subsequent interim period through ~~June~~May 13, ~~2024~~2026, ~~date of engagement,~~ neither the Company, nor anyone on ~~its~~acting on behalf, of the Company had consulted ~~Rao~~GSKCA regarding either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered ~~with~~on ~~respect to~~ the ~~consolidated~~Company’s financial statements, ofnor ~~the~~did ~~Company, and~~GSKCA noprovide a written report or oral advice ~~was provided~~ to the Company bythat ~~Rao~~GSKCA ~~that~~concluded was an important factor considered by the Company in reaching a decision as to ~~any~~the accounting, auditing or financial reporting ~~issue~~issues; or (ii) any matter that was either the subject of a "“disagreement" ” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as ~~that~~described ~~term is defined~~ in Item 304(a)(1)(v) of Regulation S-K).

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.

As of March 31, ~~2025~~2026, we carried out an evaluation, with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were not effective, as of March 31, ~~2025~~2026.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our principal executive officer [and principal financial officer], we conducted an evaluation of the effectiveness, as of March 31, ~~2025~~2026, of our internal control over financial reporting based on the framework in 2013 Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was not effective as of March 31, ~~2025~~2026 due to material weaknesses in our internal control over financial reporting described below.

Our internal controls are not effective for the following reasons: (i) there is an inadequate segregation of duties consistent with control objectives as management is comprised of only one person, the Company’s principal executive officer and principal financial officer and, (ii) the Company does not have an audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

In order to mitigate the foregoing material weaknesses, we have engaged an outside accounting consultant with significant experience in the preparation of financial statements in conformity with GAAP to assist us in the preparation of our financial statements to ensure that these financial statements are prepared in conformity with GAAP. We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate.

Table of Contents

We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will continue to reassess this matter to determine whether improvement in segregation of duty is feasible. In addition, we would need to expand our board to include independent members.

Going forward, we intend to evaluate our processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the exemption provided to issuers that are not “large , accelerated filers” nor “accelerated filers” under the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Changes in Internal Control over Financial Reporting

There was no change in our system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended March 31, ~~2025~~2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

13 14 Table of Contents

PART III.

Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth the name, age and position of each of our executive officers and directors as of the date of this report:

Name		Age		Position
Kent Rodriguez		6769		Director, President, Treasurer, Secretary

Background of Executive Officers and Directors

Our directors are elected for a term of one year and serve until such director’s successor is duly elected and qualified. Each executive officer serves at the pleasure of the Board.

Kent Rodriguez

Mr. Rodriguez joined the Company as Chief Executive Officer, Secretary, and Principal Financial Officer in May 2009. Since 1995, he has been the Managing Partner of Weyer Capital Partners, a Minneapolis-based venture capital ~~corporation~~partnership. He has a B.A. degree in Geology from Carleton College, and an Executive MBA from the Harvard Business School. Mr. Rodriguez is the related party who has provided funds to the Company, which are owed back to him and can be found within the Balance Sheets and footnotes referenced throughout this filing as related party payables.

Family Relationships

There are no family relationships among any of our executive officers or directors.

Table of Contents

Board Composition

Our business and affairs are managed under the direction of our board of directors, which presently consists of one member. Our current director will continue to serve as a director until his resignation, removal or successor is duly elected.

Our certificate of incorporation and our bylaws permit our board of directors to establish the authorized number of directors from time to time by resolution. Each director serves until the expiration of the term for which such director was elected or appointed, or until such director’s earlier death, resignation or removal.

Involvement in Certain Legal Proceedings

As of the filing of this Annual Report on Form 10-K, there are no legal proceedings, and during the past ten years there have been no legal proceedings, that are material to an evaluation of the ability or integrity of any of our directors, director nominees or executive officers.

Committees of Our Board of Directors

Our board of directors has not established any committees.

We are not a “listed company” under SEC rules and are therefore not required to have an audit committee comprised of independent directors.

We do not currently have a “financial expert” within the meaning of the rules and regulations of the SEC.

The Company has no nominating or compensation committees at this time. The entire Board participates in the nomination and audit oversight processes and considers executive and director compensation. Given the size of the Company and its stage of development, the entire Board is involved in such decision-making processes. Thus, there is a potential conflict of interest in that our directors and officers have the authority to determine issues concerning management compensation, nominations, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executive officers or directors.

Code of Business Conduct and Ethics

The Company has not as yet adopted a code of ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions as required by the Sarbanes-Oxley Act of 2002 due to our small size and limited resources and because management’s attention has been focused on matters pertaining to raising capital and the operation of the business.

Risk and Compensation Policies

The Company does not have any risk and compensation policies.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than ten percent of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

Table of Contents

To our knowledge, each of Kent Rodriguez and Douglas Barton are delinquent in filing a Form 3 report. Mr. Barton resigned from the Company’s board of directors as of July 29, 2024.

Item 11. Executive Compensation.

On an annual basis the ~~company~~Company accrues $48,000 of wages payable, or $4,000 monthly, to its CEO Kent Rodriguez. On April 1, 2020, the Company entered into an employment agreement with its CEO which designates monthly payments due to ~~CEO~~Mr. ~~Kent~~ Rodriguez in the amount of $4,000 each month. This agreement continued for four years until March 31, 2024, and was renewed for a further term on expiry.

The following table illustrates compensation accrued to the executive team during the fiscal years ended March 31, ~~2024~~2026, and ~~2023:~~2025;

Name and Principal Position	~~Year~~	~~Salary ($)~~Year	~~Bonus ($)~~	~~Stock~~Salary ~~awards~~ ($)	~~Option awards ($)~~	~~Nonequity incentive plan compensation ($)~~	~~Nonqualified deferred compensation earnings ($)~~	~~All~~Bonus ~~other compensation~~ ($)	~~Total ($)~~	Stock awards ($)		Option awards ($)		Nonequity incentive plan compensation ($)		Nonqualified deferred compensation earnings ($)		All other compensation ($)			Total ($)
Kent Rodriguez, CEO*	~~Fiscal Year ended March 31, 2025~~	~~$48~~Fiscal Year ended March 31,~~000~~ 2026	-	-$	-48,000	-	-	~~73,195(1)~~	~~$121,195~~-		-		-		-		-		73,195	(1)	$	121,195
Kent Rodriguez, CEO*	~~Fiscal Year ended March 31, 2024~~	~~$48~~Fiscal Year ended March 31,~~000~~ 2025	-	-$	-48,000	-	-	~~73,195(1)~~	~~$121,195~~-		-		-		-		-		73,195	(1)	$	121,195

*Total compensation accrued for Kent Rodriguez during each fiscal year is $48,000 total, which includes his compensation as CEO as well as Director.

(1) Included in other compensation are accrued dividends for Mr. Rodriguez ownership of 100% of the Company’s Series A Preferred shares and 18.6% of the Company’s Series B preferred shares.

Outstanding Equity Awards at Fiscal Year-End

As of March 31, ~~2025~~2026, there were no outstanding equity awards.

Director Compensation

No compensation was paid to our directors for services rendered during the years ended March 31, ~~2024~~2026, and ~~2023~~2025.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table lists, as of March 31, ~~2025~~2026, the number of shares of common stock beneficially owned by (i) each person, entity or group (as that term is used in Section 13(d)(3) of the Securities Exchange Act of 1934) known to the Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each of our Named Executive Officers and (iii) all officers and directors as a group. Information relating to beneficial ownership of common stock by our principal stockholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person directly or indirectly has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to dispose or direct the disposition of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the SEC rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary interest. Except as noted below, each person has sole voting and investment power with respect to the shares beneficially owned and each stockholder’s address is c/o Groove Botanicals Inc., 310 Fourth Avenue South, Suite ~~700~~7000, Minneapolis, MN

~~The~~17 ~~following~~Table ~~table sets forth, as~~ of ~~March 31, 2025, information regarding beneficial ownership of our capital stock by:~~Contents

The following table sets forth, as of March 31, 2026, information regarding beneficial ownership of our capital stock by:

	●	each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
	●	each of our directors;
	●	each of our named executive officers; and
	●	all of our current executive officers, and directors as a group.

In the table below, percentage ownership is based on 59,643,062 shares of our Common Stock issued and outstanding as of March 31, ~~2025~~2026, including dilutive shares available for issue withing 60 days of the date of the Report.

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all ordinary shares beneficially owned by them.

Name of Beneficial Owner	Number of ~~Shares~~SharesBeneficially ~~Beneficially~~ Owned (2)			Percentage of ~~Shares~~SharesBeneficiallyOwned ~~Beneficially Owned~~ (2)
5% or Greater Stockholders
Directors and Named Executive Officers
Kent Rodriguez, President, Secretary, Treasurer and Director		62,081,840	(1)		51.~~5101~~01%
All directors, directors nominees and executive officers as a group ( 1person):		62,081,840	(1)		.5101%
All directors, directors’ nominees and executive officers as a group (1 person):		62,081,840	(1)		51.01%

(1)	This amount includes a total of 62,077,473 common shares issuable upon conversion of 100 shares of Series A Convertible Preferred Stock and 4,367 shares of common stock held by Mr. Rodriguez.
(2)	Fully diluted shares outstanding for purposes of calculation totals 121,720,535, including 62,077,473 common shares issuable to Kent Rodriguez upon conversion of 100 shares of Series A Convertible Preferred Stock

Securities Authorized for Issuance under Equity Compensation Plans

None.

Policies and Procedures for Related Person Transactions

We do not currently have a formal, written policy or procedure for the review and approval of related party transactions. However, all related party transactions are currently reviewed, and as may be necessary, approved by our Board of Directors.

Director Independence

~~During~~Through ~~fiscal 2025, to~~ July 29, 2024 , and during the entirety of the year ended March 31, 2024 we had one independent director, Mr. Douglas Barton. Mr. Barton resigned from the Company’s board of directors as of July 29, 2024., Asfollowing atwhich ~~July~~date ~~29, 2024,~~ we ~~did~~have not ~~have~~had any independent directors.

Related Transactions

The Company had a related party payable of $~~608~~747,~~833~~ 961 and $~~453~~608,~~057~~833 outstanding as of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively. These amounts consist of funds contributed by the management for the purpose of providing financing during periods of low or negative cashflow in order to cover essential costs of continuing operations, as well as funds payable to management as compensation. On an annual basis the Company accrues $48,000 of wages payable to its CEO. Kent Rodriguez under the terms of an employment agreement with its CEO entered into April 1, 2020, which designates monthly payments due to CEO Kent Rodriguez in the amount of $4,000. This agreement continued through March 31, 2024, and was subsequently renewed. These payables accrue no interest and have no maturity date.

~~During~~18 ~~the~~Table ~~fiscal year ended March 31, 2025 and 2024, the Company accrued $40,000 in preferred dividends from the Series A preferred shares to Mr. Kent Rodriguez, the holder~~ of ~~the Series A Preferred shares. Upon conversion the number of shares of common stock to be exchanged shall equal 51% of the then fully diluted issued and outstanding common stock.~~Contents

~~The~~During ~~Company~~the ~~further~~fiscal year ended March 31, 2026 and 2025, the Company accrued $3340,~~195~~000 in preferred dividends ~~for~~ from the Series A preferred shares to Mr. Kent Rodriguez’, ~~ownership~~the ofholder ~~18.6%~~ of the Series BA Preferred ~~Shares~~shares. inUpon conversion the ~~years~~number ~~ended~~of ~~March~~shares ~~31,~~of ~~2025~~common stock to be exchanged shall equal 51% of the then fully diluted issued and ~~2024,~~outstanding ~~respectively~~common stock.

The Company further accrued $33,195 in preferred dividends for Mr. Rodriguez’ ownership of 18.6% of the Series B Preferred Shares in the years ended March 31, 2026, and 2025, respectively.

The dividends payable are reflected on the balance sheet as dividends payable related party which total $219,585 and $146,390 at March 31, 2026 and 2025, respectively.

Item 14. Principal Accounting Fees and Services

Prior Audit Firm

On May 813, ~~2024~~2026, M. S. Madhava Rao, Chartered Accountant (PCAOB ID 06662) (“Madhava Rao”) resigned as the ~~Board~~independent ofregistered ~~Directors~~public accounting firm of Groove Botanicals , Inc., a Nevada corporation (the “Company”), ~~approved~~effective immediately. On the ~~dismissal~~same ofdate, BFthe ~~Borgers~~Company’s ~~CPA~~Board PCof ~~(“BF~~Directors, ~~Borgers”)~~which also serves as the Company’s ~~independent registered~~audit ~~public~~committee, ~~accounting~~accepted ~~firm~~Madhava Rao’s resignation.

Madhave Rao was the auditor for the Company for the fiscal year ending March 31, 2025.

Current Audit Firm

On ~~June~~May 13, ~~2024~~2026, concurrently with its acceptance of Madhava Rao’s resignation, the Board of Directors of ~~Groove~~the ~~Botanicals~~Company ~~Inc.~~ (acting in its capacity as the “Company”’s audit committee) approved the ~~appointment~~engagement of ~~M.S.~~GSKCA ~~Madhava~~& ~~Rao,~~Associates ~~Chartered Accountant~~ (“~~Rao~~GSKCA”) as the Company'’s new independent registered public accounting firm, effective immediately~~, to perform independent review and audit services for the fiscal years ending March 31, 2024 and 2023~~.

~~Rao~~GSKCA is the ~~current~~Company’s auditor ~~for~~ ~~the Company~~ for the fiscal year ~~ending~~ended March 31, ~~2025~~2026.

Fees Billed to the Company in fiscal year ~~2025~~2026 and 2025

The following table sets forth the fees billed to us by current auditor GSKCA for professional services rendered during the fiscal year ended March 31, 2026 and by M.S. Madhava Rao, for professional services rendered for the fiscal ~~year~~ years ended March 31, ~~2025~~2026 and March 31, ~~2024~~2025.

	March 31, 2025		March 31, 2024
	March 31, 2026		March 31, 2025
Audit fees(1)	$	2826,500	$	2928,~~000~~500
Audit related fees(2)		—		—
Tax fees(3)		—		—
All other fees		—		—
Total fees	$	2826,500	$	2928,~~000~~500

(1)	Audit Fees — Audit fees consist of fees billed for the audit of our annual financial statements and the review of the interim consolidated financial statements. During the fiscal year ended March 31, 2026, we accrued $7,500 for audit fees for GSKCA and M.S. Madhava Rao invoiced $19,000 for audit fees.
(2)	Audit-Related Fees — These consisted principally of the aggregate fees related to audits that are not included Audit Fees.
(3)	Tax Fees — Tax fees consist of aggregate fees for tax compliance and tax advice, including the review and preparation of our tax returns

17 19 Table of Contents

PART IV.

Item 15. Exhibits and Financial Statement Schedules.

(a) List of Financial Statements, Financial Statement Schedules and Exhibits.

(1) Financial Statements. The following financial statements of Groove Botanicals Inc. are included in this Annual Report beginning on page F-1:

	~~Page~~	Page
For the Years Ended March 31, 2025 and 2024
For the Years Ended March 31, 2026 and 2025
Report of Independent Registered Public Accounting Firm (PCAOB ID: 6662)
Report of Independent Registered Public Accounting Firm (PCAOB ID: 7429)		21-23
Consolidated Balance Sheets		24
Consolidated Statements of Operations		25
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)		26
Consolidated Statements of Cash Flows		27
Notes to Consolidated Financial Statements		28

18 20 Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

July 15, 2025

Audit Committee/Board of Director

Groove Botanicals, Inc.

310 Fourth Avenue South, Suite 7000

Minneapolis, MN 55415

Opinion on the financial statements

We audited the accompanying balance sheets of Groove Botanicals, Inc. (“the Company”) as of March 31, 2025 and 2024 and the related statements of operations, stockholders’ equity, and cash flows for years then ended and the related notes (collectively referred to as “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2025 and 2024, and the results of its operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of the liabilities in the normal course of business. The Company has an accumulated deficit of $35,196,581 for the year ended March 31, 2025. These factors as discussed in Note 3 of the financial statements raise substantial doubt about the Company’s ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis of Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits. we are required to obtain an understanding of internal control over financial reporting not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters arising from the current period of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosure that are material to the financial statements and (2) involve especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit below, providing separate opinions on the critical audit matters or the accounts or disclosures to which they relate.

Related party transactions.

As discussed in Note 5 to the financial statement, the Company has borrowed from related parties an amount $608,833 as of the date of March 31, 2025. The procedure performed to address the matter included: obtaining confirmation from related party.

We have served as the Company’s auditor since 2024.

/s/ M. S. Madhava Rao

M. S. Madhava Rao, Chartered Accountant

Bangalore, India

July 15, 2025

19 21 Table of Contents

~~Groove~~Report ~~Botanicals,~~of ~~Inc. Consolidated~~Independent ~~Balance~~Registered ~~Sheets~~Public Accounting Firm

	March 31, 2025			March 31, 2024
ASSETS
Current Assets:
Cash	$	2,042		$	1,688
Prepaid Expenses		2,478			454
Total Current Assets		4,520			2,142
TOTAL ASSETS	$	4,520		$	2,142
LIABILITIES & STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable and Accrued Liabilities	$	68,608		$	91,172
Related Party Payable		608,833			453,057
Dividends payable		356,940			178,470
Dividends payable, related party		80,000			40,000
Total Current Liabilities		1,114,381			762,699
Total Liabilities		1,114,381			762,699
Stockholders’ Equity
Preferred Stock, Series A, $0.10 par value, 100 shares authorized; 100 shares issued and outstanding as of March 31, 2025, and March 31, 2024		10			10
Preferred Stock, Series B, $0.10 par value, 2,000 shares authorized; 1,983 shares issued and outstanding as of March 31, 2025, and March 31, 2024		198			198
Common Stock, $0.001 par value, 200,000,000 shares authorized. and 59,643,062 shares issued and outstanding as of March 31, 2025, and March 31, 2024		59,643			59,643
Additional paid-in capital		34,026,869			34,026,869
Accumulated deficit		(35,196,581	)		(34,847,277	)
Total stockholder’s equity		(1,109,861	)		(760,557	)
TOTAL LIABILITIES AND STOCKHOLDER’S DEFICIT	$	4,520		$	2,142

To the Board of Directors,

Groove Botanicals Inc.

310 Fourth Avenue South

Suite 7000

Minneapolis MN, 55415

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Groove Botanicals, Inc. (the “Company”) as of March 31, 2026, the related statement of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $139,917 and $130,834 for the years ended March 31, 2026, and March 31, 2025, respectively. The Company’s accumulated deficit was $35,554,968 and $35,196,581 as of March 31, 2026, and March 31, 2025, respectively. These Factors raises substantial doubt about the Company’s ability to continue as a going concern. Management’s plans with regard to these matters are also described in Note 3. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

Basis for Opinion-

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

HO: 913, Skye Corporate Park, Plot No. 25, Scheme No. 78 Part-2, Niranjanpur, A B Road, Indore (M.P.)-452001 Branch: Aklera (Rajasthan)

Tele: 0731-4969499 | 9179664633 | 7415159295 | 8982305103

Email: [email protected] | Web: www.gskca.com

Table of Contents

Critical Audit Matters

Critical audit matter arising from the current period of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involve especially challenging, subjective, or complex judgements. The communication of critical audit matter does not alter in any way our opinion on the financial statements taken as a whole, and we are not, by communicating the critical audit below, providing separate opinions on the critical audit matters or the accounts or disclosures to which it relates.

Related party transactions

As discussed in Note 5 to the financial statements, the Company had amounts due to related parties and accrued salaries totaling $747,961 as of March 31, 2026. The procedure performed to address the matter included: obtaining confirmation from related party.

GSKCA & Associates (PCAOB ID 7429)

Indore, India

June 29, 2026

We have served as the Company’s auditor since 2026.

HO: 913, Skye Corporate Park, Plot No. 25, Scheme No. 78 Part-2, Niranjanpur, A B Road, Indore (M.P.)-452001 Branch: Aklera (Rajasthan)

Tele: 0731-4969499 | 9179664633 | 7415159295 | 8982305103

Email: [email protected] | Web: www.gskca.com

Table of Contents

Groove Botanicals, Inc.

Consolidated Balance Sheets

	March 31, 2026			March 31, 2025
ASSETS
Current Assets:
Cash	$	1,502		$	2,042
Prepaid Expenses		2,930			2,478
Total Current Assets		4,432			4,520
TOTAL ASSETS	$	4,432		$	4,520

LIABILITIES & STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable and Accrued Liabilities	$	69,309		$	68,608
Related Party Payable		747,961			608,833
Dividends payable		435,825			290,550
Dividends payable, related party		219,585			146,390
Total Current Liabilities		1,472,680			1,114,381
Total Liabilities		1,472,680			1,114,381

Stockholders’ Equity
Preferred Stock, Series A, $0.10 par value, 100 shares authorized; 100 shares issued and outstanding as of March 31, 2026, and March 31, 2025		10			10
Preferred Stock, Series B, $0.10 par value, 2,000 shares authorized; 1,983 shares issued and outstanding as of March 31, 2026, and March 31, 2025		198			198
Common Stock, $0.001 par value, 200,000,000 shares authorized. and 59,643,062 shares issued and outstanding as of March 31, 2026, and March 31, 2025		59,643			59,643
Additional paid-in capital		34,026,869			34,026,869
Accumulated deficit		(35,554,968	)		(35,196,581	)
Total stockholder’s equity		(1,468,248	)		(1,109,861	)
TOTAL LIABILITIES AND STOCKHOLDER’S DEFICIT	$	4,432		$	4,520

The accompanying notes are an integral part of these consolidated financial statements.

20 24 Table of Contents

Groove Botanicals, Inc. ~~Consolidated~~ ~~Statements of Operations~~

	For the Years Ended March 31,
	2025			2024
Expenses:
Selling, General and Administrative Expenses	$	73,087		$	73,743
Rent		15,435			18,576
Legal and Professional Expenses		42,312			95,962
Consulting Expense		—			78,300
Total operating expenses		130,834			266,581
Operating loss		(130,834	)		(266,581	)
Other Income (Expense)
Gain on Settlement of Debt		—			71,242
Interest Income (Expense)		—			(6,750	)
Total Other Income (Expense)		—			64,492
Net (loss)	$	(130,834	)	$	(202,089	)
Dividend on Preferred Stock		(218,470	)		(218,470	)
Net (loss) attributable to common shareholders	$	(349,304	)	$	(420,559	)
Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)
Weighted average common shares outstanding – Basic and diluted		58,880,767			58,880,767

Consolidated Statements of Operations

	For the Years ended, March 31,
	2026			2025

Expenses:
Selling, General and Administrative Expenses	$	73,774		$	70,087
Rent		14,400			15,435
Legal and Professional Expenses		43,743			42,312
Consulting Expense		8,000			3,000
Total Operating Expenses		139,917			130,834

Operating Loss		(139,917	)		(130,834	)
Interest Expense		-			-
Net (Loss)	$	(139,917	)		(130,834	)

Dividend on Preferred Stock		(218,470	)		(218,470	)
	$	(358,387	)	$	(349,304	)

Basic and Diluted Earnings (Loss) per Common Share	$	(0.01	)	$	(0.01	)

Weighted Average Common Shares Outstanding – Basic and diluted		59,643,062			59,643,062

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

Groove Botanicals, Inc.

Consolidated Statements of Stockholders’ Equity

For the Years Ended March 31, 2026, and 2025

													Additional
	Series A				Series B								Paid In		Accumulated
	Preferred Stock				Preferred Stock				Common Stock				Capital		Deficit			Total
	Shares		Amount		Shares		Amount		Shares		Amount		Amount		Amount			Amount
Balance, March 31, 2024		100	$	10		1,983	$	198		59,643,062	$	59,643	$	34,026,869	$	(34,847,277	)	$	(760,557	)
Accrued dividend		-		-		-		-		-		-		-		(218,470	)		(218,470	)
Net (loss)		-		-		-		-		-		-		-		(130,834	)		(130,834	)
Balance, March 31, 2025		100	$	10		1,983	$	198		59,643,062	$	59,643	$	34,026,869	$	(35,196,581	)	$	(1,109,861	)
Accrued dividend		-		-		-		-		-		-		-		(218,470	)		(218,470	)
Net (loss)		-		-		-		-		-		-		-		(139,917	)		(139,917	)
Balance, March 31, 2026		100	$	10		1,983	$	198		59,643,062	$	59,643	$	34,026,869	$	(35,554,968	)	$	(1,468,248	)

The accompanying notes are an integral part of these consolidated financial statements.

21 26 Table of Contents

Groove Botanicals, Inc. ~~Consolidated~~ ~~Statements of Stockholders’ Equity For the Years Ended March 31, 2024, and 2023~~

	Series A Preferred Stock			Series B Preferred Stock			Common Stock			Additional Paid In Capital		Accumulated Deficit			Total
	Shares	Amount		Shares	Amount		Shares	Amount		Amount		Amount			Amount
Balance, March 31, 2023	100	$	10	1,983	$	198	57,643,062	$	57,643	$	33,930,569	$	(34,426,718	)	$	(438,298	)
Issuance of Stock for Cash							1,000,000		1,000		19,000					20,000
Issuance of Stock for Consulting							1,000,000		1,000		77,300					78,300
Accrued dividend													(218,470	)		(218,470	)
Net (loss)			-			-			-		-		(202,089	)		(202,089	)
Balance, March 31, 2024	100		10	1,983		198	59,643,062		59,643		34,026,869		(34,847,277	)		(760,557	)
Accrued dividend													(218,470	)		(218,470	)
Net (loss)			-			-			-		-		(130,834	)		(130,834	)
Balance, March 31, 2024	100	$	10	1,983	$	198	59,643,062	$	59,643	$	34,026,869	$	(35,196,581	)	$	(1,109,861	)

Consolidated Statements of Cash Flows

	For the Years Ended March 31,
	2026			2025
Cash Flow From Operating Activities
Net Loss	$	(139,917	)	$	(130,834	)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued Payroll		48,000			48,000
Changes in working capital
Decrease (Increase) in Prepaid Expenses		(452	)		(2,024	)
Increase (Decrease) in Accounts Payable and Accrued Liabilities		701			(22,564	)
Net Cash Used in Operating Activities		(91,668	)		(107,422	)

Cash Flow From Financing Activities
Funds received from Related Party		95,320			107,776
Funds distributed to Related Party		(4,192	)		-
Net Cash From Financing Activities		91,128			107,776

Net Change in Cash		(540	)		354

Cash at Beginning of Year		2,042			1,688

Cash at End of Period	$	1,502		$	2,042

Supplemental disclosure of non-cash items:
Accrued dividends on preferred stock	$	218,470		$	218,470

Net cash paid for:
Interest	$	—		$	—
Income Taxes	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

22 27 Table of Contents

Groove Botanicals, Inc. Consolidated Statements of Cash Flows

	For the Years Ended March 31,
	2025			2024
Cash Flow From Operating Activities
Net Loss	$	(130,834	)	$	(202,089	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock Issued for Outside Services		—			78,300
Gain on Settlement of Debt		—			(71,242	)
Accrued Interest		—			6,750
Accrued Payroll		48,000			48,000
Changes in working capital
Increase in Prepaid Expenses		(2,024	)		28
Increase (Decrease) in Accounts Payable and Accrued Liabilities		(22,564	)		53,418
Net Cash Used in Operating Activities		(107,422	)		(86,835	)
Cash Flow From Investing Activities
Net Cash From Investing Activities		—			—
Cash Flow From Financing Activities
Funds received from Related Party		107,776			104,915
Funds distributed to Related Party		—			(958	)
Repayment of Outstanding Convertible Debt		—			(40,000	)
Funds received for Issuance of Common Stock		—			20,000
Net Cash From Financing Activities		107,776			83,957
Net Change in Cash		354			(2,878	)
Cash at Beginning of Period		1,688			4,566
Cash at End of Period	$	2,042		$	1,688
Net cash paid for:
Interest	$	—		$	—
Income Taxes	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

GROOVE BOTANICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED MARCH 31, ~~2025~~2026, AND ~~2024~~2025

NOTE 1 – ORGANIZATION AND OPERATIONS

Current Operations

Groove Botanicals, Inc. (the “Company”), (formerly known as Avalon Oil & Gas, Inc.), was originally incorporated in Colorado on April 25, 1991, under the name Snow Runner (USA), Inc. The Company was the general partner of Snow Runner (USA) Ltd.; a Colorado limited partnership to sell proprietary snow skates under the name “Sled Dogs” which was dissolved in August 1992. In late 1993, the Company relocated its operations to Minnesota and in January 1994 changed our name to Snow Runner, Inc. In November 1994 we changed our name to the Sled Dogs Company. On May 25, 1999, we filed articles of merger with Xdogs.com Inc., changing our state of domicile to Nevada. On June 22, 2005, the Corporation changed our name from XDOGS.com, Inc. to Avalon Oil and Gas, Inc. On May 14, 2018, the Corporation changed our name from Avalon Oil and Gas, Inc., to Groove Botanicals, Inc. Until August 2, 2021, when we filed a 15-12B to suspend duty to file reports under sections 13 and 15(d) of the securities exchange act of 1934, we were a reporting company. Subsequently, on September 14, 2023, we filed a Form 10 with the Securities and Exchange Commission, which became effective 60 days later.

Since inception we have operated unsuccessfully, in various different industries. Currently, wethe ~~plan~~Company intends to ~~assemble~~change aour ~~portfolio~~name ~~of early-stage EV Battery Technologies developed~~ from ~~Universities~~Groove ~~in Norway~~Botanicals, Sweden and Finland, and seek grants from the State of Minnesota Department of Economic Development to find and identify corporate partners to commercialize these technologies and ultimately produce revenues for the CompanyInc. ~~The Company does not currently own any patents or technologies related to the EV battery industry~~, ~~and the process~~ to ~~acquire~~Nordmark ~~patents and technologies can be costly~~Technologies, ~~and as such~~Inc., ~~the Company is not guaranteed~~ to ~~acquire~~better ~~any~~describe ~~such~~our ~~patents~~corporate focus.

We have not entered into any licensing agreements or formal arrangements with any of these institutions or any other Norwegian research organization, have not identified any specific technology or intellectual property rights under contract, and do not have proprietary or exclusive access to any technology pipeline.

We are in an early stage of development, we have not entered into any licensing agreements or formal arrangements with any university, research institution, or technology transfer organization to date, and there can be no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.

On July 29, 2024, Mr. Douglas Barton resigned as a director of the Company.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United ~~Stated~~States of America (“U.S. GAAP”) for financial information. Accordingly, they include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The consolidated financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the financial statements not misleading. The consolidated balance sheets as of March 31, ~~2025~~2026 and ~~2024~~2025, were derived from the Company’s consolidated financial statements at that date.

Basis of Consolidation

The Company’s consolidated financial statements include the accounts of Groove Botanicals, Inc., and its two 100% controlled non-operating subsidiaries formed in Wyoming, Biotrex, Inc., and Maxidyne, Inc. Intercompany accounts and transactions have been eliminated in consolidation.

Table of Contents

GROOVE BOTANICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED MARCH 31, 2026, AND 2025

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of Estimates

24 Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-year presentation. These reclassifications had no effect on previously reported net loss, total stockholders’ equity, or accumulated deficit.

Financial Instruments

The Company'’s financial instruments primarily consist of cash and cash equivalents, accounts payable and accrued liabilities, related party payables, dividends payable and other debt. The carrying values of the Company'’s financial instruments approximate fair value. FASB ASC 820, Fair Value Measurements and Disclosures ("“ASC 820"”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories: Level 1—Quoted market prices for identical assets or liabilities in active markets or observable inputs; Level 2—Significant other observable inputs that can be corroborated by observable market data; and Level 3—Significant unobservable inputs that cannot be corroborated by observable market data. The Company believes that the carrying amounts of cash and cash equivalents, accounts payable, related party payables, accrued dividends and debt approximate fair value based on either their short-term nature or on terms currently available to the Company in financial markets.

Net Loss Per Share

The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As the Company has continued to report operating losses for the periods covered by this report, the impact of potentially dilutive securities would be anti-dilutive and therefore is not presented.

Income Taxes

The Company is taxed as a C corporation for income tax purposes. The Company accounts for income taxes under the liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the deferred tax asset will not be realized. The Company records interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense. The Company records tax positions taken or expected to be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the resolution of any related appeals or other legal processes. Accordingly, the Company recognizes liabilities for certain unrecognized tax benefits based on the amounts that are more likely than not to be settled with the relevant taxing authority. The Company recognizes interest and/or penalties related to unrecognized tax benefits as a component of income tax expense.

Table of Contents

GROOVE BOTANICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED MARCH 31, 2026, AND 2025

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes (Cont’d)

The Company records interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense. The Company records tax positions taken or expected to be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the resolution of any related appeals or other legal processes. Accordingly, the Company recognizes liabilities for certain unrecognized tax benefits based on the amounts that are more likely than not to be settled with the relevant taxing authority. The Company recognizes interest and/or penalties related to unrecognized tax benefits as a component of income tax expense.

Recent Accounting Standard Adopted:

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 – Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim financial statements, including additional, more detailed information about a reportable segment’s expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the year ended March 31, 2025, retrospectively to all periods presented in the financial ~~statement~~statements. The adoption of this ASU had no impact on reportable segments identified and had no effect on the Company’s financial position, results of operations, or cash flows.

~~Recent~~In December 2023, the Financial Accounting ~~Standard~~Standards ~~Not~~Board ~~Yet~~issued ~~Adopted:~~Accounting Standards Update (“ASU”) 2023-09 – Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2024. Early adoption is available. The Company adopted ASU 2023-09 for the year beginning April 1, 2025. The adoption of this ASU had no impact on the Company’s financial position, results of operations, or cash flows.

InRecent ~~December 2023, the Financial~~ Accounting Standards ~~Board issued~~Not ~~Accounting~~Yet Standards Update (“ASU”) 2023-09 – Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2024. Early adoption is available. The Company is still evaluating the full extent of the potential impact of the adoption of ASU 2023-09, but believes it will not have a material impact on its financial statements and disclosures.Adopted:

25 In November 2024, the FASB issued ASU 2024-03, – Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company will evaluate the full extent of the adoption of ASU 2024-03 but believes it will not have a material impact on its consolidated financial statements and disclosures.

In November 2024, the FASB issued ASU 2024-03, – Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company will evaluate the full extent of the adoption of ASU 2024-03, but believes it will not have a material impact on its consolidated financial statements and disclosures.

NOTE 3 – GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $~~130~~139,~~834~~917 and $~~202~~130,~~089~~834 for the years ended March 31, ~~2025~~2026, and March 31, ~~2024~~ 2025, respectively. The Company’s accumulated deficit was $35,~~196~~554,~~581and~~968 and $3435,~~847~~196,~~277~~581 as of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing. Our auditors express substantial doubt about our ability to continue as a going concern.

Table of Contents

GROOVE BOTANICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED MARCH 31, 2026, AND 2025

NOTE 4 – CASH

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, ~~2025~~2026, the Company’s cash consisted of non-restricted cash.

NOTE 5 – RELATED PARTY TRANSACTIONS

The Company had related party payables of $~~608~~747,~~833~~ 961 and $~~453~~608,~~057~~ 833 as of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively. These amounts consist of funds contributed by the management for the purpose of providing financing during periods of low or negative cashflow in order to cover essential costs of continuing operations, as well as funds payable to management as compensation. On an annual basis the Company accrues $48,000 of wages payable to its CEO, Kent Rodriguez, under the terms of a four-year employment agreement entered into April 1, 2020, which designates monthly payments due Mr. Rodriguez in the amount of $4,000. On July 30, 2024, the Company and Mr. Kent Rodriguez agreed to extend the term of this Employment Contract, which expired on March 31, 2024, for a further two-year term to March 31, 2026, retroactive to April 1, 2024, on the same terms and conditions.

During each of the fiscal years ended March 31, ~~2025,~~2026 and ~~2024~~ 2025, the Company accrued $40,000 in preferred dividends from the Series A preferred shares to Mr. Kent Rodriguez, the sole shareholder of the Series A Preferred shares. Upon conversion the number of shares of common stock to be exchanged for the Series A Preferred shares shall equal 51% of the then fully diluted issued and outstanding common stock at the time of conversion. Further the Company accrued dividends of $33,195 in each of the fiscal years ended March 31, ~~2025~~2026, and ~~2024~~2025 with respect to 18.6% of the Series B Preferred shares controlled by Kent Rodriguez.

NOTE 6 – ~~CONVERTIBLE~~PREFERRED ~~NOTES PAYABLE~~STOCK

~~Convertible~~The ~~notes~~Company ~~payable~~is ~~consisted~~authorized ofto aissue ~~$40~~1,000 ~~Convertible Promissory Note issued on March 5~~,000 ~~2021,~~shares byof ~~management~~Preferred ~~to a third party in exchange for professional services~~Stock. ~~Beginning~~We onhave ~~the~~authorized ~~issuance date~~100 ofshares ~~this note, the outstanding principal balance~~ of ~~this~~Series ~~note~~A ~~shall~~Preferred ~~bear~~Stock ~~annual~~and ~~interest at 10%~~2,000 ~~with~~shares ~~interest commencing on the sixth month anniversary~~ of ~~the~~Series ~~Issuance~~B ~~Date.~~Preferred ~~The note had a maturity date of June 30~~Stock, ~~2022. Additionally~~respectively, ~~the~~both ~~note~~with ~~has~~ a ~~fixed conversion~~par ~~feature~~value of $0.~~02 per share, and therefore the Convertible Note is measured at the net of Debt Discount, calculated based off its Beneficial Conversion Features~~10. ~~The note was booked with a debt discount of the full principal balance of $40,000.~~ As of ~~June 30, 2022, this entire debt discount had been amortized. Further, on~~ March 731, ~~2022,~~2026 ~~the~~and ~~Company issued an additional convertible promissory note in the amount of $60,000, with a maturity date of~~ March 731, ~~2023~~2025, anthere ~~annual~~were ~~interest~~100 ~~rate of 10%~~ and ~~a fixed conversion price of $0.02 per share~~1,983 inshares ~~exchange~~issued ~~for~~and ~~consulting~~outstanding ~~services. The convertible amount is accounted~~ for ~~based~~Series ~~off~~A ~~the~~Preferred ~~outstanding principal~~Stock and ~~related~~Series ~~interest~~B ~~pertaining~~Preferred ~~to the portion convertible debt instrument being converted~~Stock, ~~multiplied by the previously specified conversion rate~~respectively.

OnSeries ~~July~~A 18Preferred Stock holds designations of cash dividends at the rate of 8% of the amount per share of Series A Preferred Stock per annum in the form of “Preferred Dividends”, ~~2022~~voting rights on an as-converted to Common Stock basis, aliquidation ~~Letter~~preferences, ~~Agreement~~and ~~was~~conversion ~~drafted~~rights ~~between~~in which each share of Series A Preferred Stock shall, upon conversion, represent 0.51% of the then “Fully-Diluted Shares Outstanding” of the Company. ~~and~~On January 12, 2018, our Board of Directors agreed to amend Designation of the ~~debtholder~~Series A Convertible Preferred Stock be amended by changing the ratio for conversion, ~~which~~in ~~establishes~~Article IV, subparagraph (a), from 0.4% to 0.51% so that upon conversion the ~~settlement~~number of ~~these~~shares ~~debts~~of ~~once~~common stock to be exchanged shall equal 51% of the ~~Company’s~~then ~~Form~~issued 10and ~~goes~~outstanding ~~effective~~common stock. OnIn addition, on January 23 12, ~~2023~~2018, the Company and the ~~convertible~~Series ~~note~~A ~~holder~~Holder ~~mutually~~ agreed to ~~settle~~forgive ~~any~~all ~~and~~accrued ~~all~~interest ~~amounts~~to ~~owed~~date ~~pursuant~~on Series A, and to pause any accruals until April 1), ~~the~~2023. ~~Consulting Agreement~~The ~~and~~Series A Convertible ~~Promissory~~Preferred ~~Note~~Stock incarries liquidating preference, over all other classes of stock, equal to the amount paid for the stock plus any unpaid dividends. Currently the value of the liquidation preference is $40500,000 ~~dated~~, ~~March~~the 5,amount ~~2021;~~of ~~and~~debt 2)that the ~~Consulting~~related ~~Agreement~~party ~~and~~converted ainto ~~Convertible Promissory~~the ~~Note~~preferred instock. If this Preferred Stock were to be redeemed by the ~~amount~~holder, it would result in an aggregate of the $60500,000 ~~dated~~ ~~March~~liquidation 7preference, ~~2022;~~on 3)a per share basis, this would equal $5,000 per share. The Company and Series A Preferred Holder agreed to forgive all accrued interest ~~accrued~~and arrearages in preferred share dividends of Series A Preferred Stock through ~~settlement~~March ~~date~~31, 2023. Dividends began to accrue on the Series A Preferred Stock as ~~follows:~~of ~~$10~~April 1,~~000~~ 2023.~~00 to~~ beDuring ~~paid~~the toyears ~~Hymers~~ended ~~upon~~March ~~execution~~31, 2026 and 2025, the holder of ~~this~~the ~~Agreement~~Series A preferred shares, ~~with~~Mr. anKent ~~additional~~Rodriguez, ~~payment~~CEO, ofaccrued $40,000 30and ~~days~~$40,000 ~~after~~respectively ~~GRVE’s~~in ~~Form~~preferred 10dividends ~~has~~from ~~gone effective~~the Series A preferred shares. A total of $120,000 and $80,000 in accrued dividends with respect to the Series A preferred shares held by Mr. Rodriquez was outstanding at March 31, 2026, and March 31, 2025, respectively.

26 31 Table of Contents

~~$10,000 was~~GROOVE ~~paid on January 24~~BOTANICALS, ~~2023~~INC. $40,000 was paid on December 31, 2023. This resulted in a gain on the settlement of debt in the amount of $71,242, including interest forgiven of $21,242, during the fiscal year ended March 31, 2024.

AsNOTES ofTO ~~March~~CONSOLIDATED ~~31,~~FINANCIAL ~~2025 and March 31, 2024, the balance of the convertible note was $0.~~STATEMENTS

~~NOTE~~FOR 7THE –YEARS ~~PREFERRED~~ENDED ~~STOCK~~MARCH 31, 2026, AND 2025

~~The~~NOTE ~~Company~~6 is– ~~authorized~~PREFERRED toSTOCK issue 1,000,000 shares of Preferred Stock. We have authorized 100 shares of Series A Preferred Stock and 2,000 shares of Series B Preferred Stock, respectively, both with a par value of $0.10. As of March 31, 2025, and March 31, 2024, there were 100 and 1,983 shares issued and outstanding for Series A Preferred Stock and Series B Preferred Stock, respectively.(continued)

Series AB Preferred Stock holds designations of being ranked junior to the Series A Preferred Stock, cash dividends at the rate of 89% of the amount per share of Series AB Preferred Stock per annum in the form of “Preferred Dividends”, ~~voting rights~~a ondividend anreceived ~~as-converted~~deduction tofor ~~Common~~federal ~~Stock~~income ~~basis~~tax purposes, liquidation preferences, ~~and~~ranked ~~conversion~~junior ~~rights~~to inthe ~~which each share of~~ Series A Preferred ~~Stock~~ ~~shall~~Stock, ~~upon~~redemption ~~conversion, represent 0.51%~~ of the ~~then~~Series ~~“Fully-Diluted~~B ~~Shares~~Preferred ~~Outstanding”~~Stock ofby the Company. Onat ~~January~~105% ~~12, 2018, our Board~~ of ~~Directors agreed to amend Designation of~~ the ~~Series~~Stated ~~A Convertible Preferred Stock be amended by changing the ratio for conversion~~Value, inplus ~~Article~~accrued ~~IV,~~and ~~subparagraph~~unpaid ~~(a)~~Dividends, ~~from~~if ~~0.4%~~prior to ~~0.51% so that upon conversion~~ the ~~number~~two ofyear ~~shares~~anniversary of ~~common~~the ~~stock~~Issuance toDate, ~~be exchanged~~or ~~shall~~at ~~equal 51~~100% of the ~~then~~State ~~issued and outstanding common stock. In addition~~Value, onplus ~~January 12, 2018, the Company and the Series A Holder agreed to forgive all~~ accrued ~~interest to date on Series A,~~ and tounpaid ~~pause any accruals until April 1~~Dividends, ~~2023.~~if ~~The~~on ~~Series~~or Aafter ~~Convertible Preferred Stock carries liquidating preference, over all other classes of stock, equal to~~ the ~~amount~~two ~~paid~~year ~~for~~anniversary ~~the stock plus any unpaid dividends. Currently the value~~ of the ~~liquidation~~Issuance ~~preference is $500~~Date,~~000,~~ ~~the~~no ~~amount~~voting ofrights, ~~debt~~and ~~that~~right ~~the~~to ~~related~~notice ~~party~~of ~~converted~~certain ~~into~~corporate ~~the preferred stock~~actions. IfAll ~~this~~accrued ~~Preferred~~dividends ~~Stock~~on ~~were to be redeemed by~~ the ~~holder,~~Series itB ~~would~~were ~~result~~settled inthrough anMarch ~~aggregate of the $500~~31,~~000~~ ~~liquidation preference~~2023, ~~on a per share basis, this would equal $5,000 per share. The Company~~ and ~~Series~~none Aremained ~~Preferred~~outstanding ~~Holder~~at ~~agreed to forgive all accrued interest and arrearages in preferred share dividends of Series A Preferred Stock through~~ March 31, 2023. Dividends began to accrue on the Series AB Preferred Stock as of April 1, 2023. During the ~~fiscal~~years ~~year~~ ended March 31, ~~2025,~~2026 and ~~2024~~2025, the ~~holder~~holders of the Series A B preferred shares accrued $40178,~~000~~470 in preferred dividends from the Series AB preferred shares. A total of $80535,~~000~~410 and $40356,~~000~~940 in Preferred B dividends was outstanding at March 31, ~~2025~~2026 and March 31, ~~2024~~2025, respectively, including dividends accrued for the benefit of Mr. Kent Rodriguez, CEO, of $33,195 for each respective year ended March 31, 2026 and 2025. Mr. Rodriguez holds 18.6% of the Series B preferred shares.

~~Series~~A Bsummary ~~Preferred Stock holds designations~~ of ~~being~~accrued ~~ranked junior to the Series A Preferred Stock, cash~~ dividends atpayable ~~the~~with ~~rate~~respect of 9% of the amount per share of Series B Preferred Stock per annum in the form of “Preferred Dividends”, a dividend received deduction for federal income tax purposes, liquidation preferences ranked junior to the Series A ~~Preferred~~and ~~Stock, redemption of the Series~~ B Preferred ~~Stock~~shares byon the Company’s atbalance ~~105%~~sheets ofare ~~the~~set ~~Stated~~out ~~Value, plus~~below. ~~accrued and unpaid~~ Dividends, ~~if prior to the two year anniversary of the Issuance Date, or at 100% of the State Value, plus~~ accrued ~~and~~ ~~unpaid~~for ~~Dividends, if on or after~~ the ~~two~~benefit ~~year anniversary~~ of the ~~Issuance~~Company’s ~~Date,~~CEO noare ~~voting~~included ~~rights,~~in ~~and right to notice of certain corporate action. All accrued dividends on the Series B were settled through March 31, 2023, and none remained outstanding at March 31, 2023.~~ Dividends ~~began~~ ~~to accrue on the Series B Preferred Stock as of April 1~~payable, ~~2023.~~related During the fiscal year ended March 31, 2025 and 2024, the holder of the Series B preferred shares accrued $178,468, in preferred dividends from the Series B preferred shares. A total of $356,940 and $178,470 in dividends was outstanding at March 31, 2025 and March 31, 2024, respectively.party:

NOTE 8 – COMMON STOCK

Schedule of dividends payable, related party
	March 31, 2026 $		March 31, 2025 $
Dividends payable		435,825		290,550
Dividends payable, related party		219,585		146,390

NOTE 7 – COMMON STOCK

The Company is authorized to issue 200,000,000 shares of Common Stock, with a par value of $0.001.

The Company did not issue any shares of common stock during the years ended March 31, 2026 or 2025, and had 59,643,062 shares of common stock issued and outstanding as of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, respectively.

OnNOTE ~~April~~8 ~~15,~~– ~~2023,~~COMMITMENTS ~~the~~AND ~~Company issued 1,000,000 shares of common stock in exchange for consulting services. These shares were valued at $0.0783 per share, the fair market value on the date of issuance.~~CONTINGENCIES

~~NOTE~~As 9of –March ~~COMMITMENTS~~31, ~~AND~~2026, ~~CONTINGENCIES~~the Company has a month-to-month verbal lease agreement with the landlord, in which the Company pays $1,200 on a monthly basis.

AsNOTE of9 ~~March~~– ~~31,~~SUBSEQUENT ~~2025, the Company has a month-to-month verbal lease agreement with the landlord, in which the Company pays $1,200 on a monthly basis.~~EVENTS

~~NOTE~~Management 10has –evaluated ~~SUBSEQUENT~~subsequent ~~EVENTS~~events pursuant to the requirements of ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing.

~~Management~~32 ~~has~~Table ~~evaluated subsequent events pursuant to the requirements~~ of ~~ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing other than as set out below.~~Contents

(2) Financial Statement Schedules.

Schedules required by this item have been omitted since they are either not required or not applicable or because the information required is included in the consolidated financial statements included elsewhere herein or the notes thereto.

(3) Exhibits.

The following exhibits are filed with this Annual Report on Form 10-K or are incorporated herein by reference, as indicated.

Exhibit Number		Exhibit Description
3.1(a)		Articles of Incorporation*
3.1(b)		Articles of Merger*
3.1(c)		Agreement and Plan of Merger*
3.1(d)		Amended Articles of Incorporation*
3.1(e)		Amended and Restated Certificate of Incorporation of the Registrant*
3.2		Bylaws of the Registrant*
4.1(a)		Certificate of Designation of Series and Determination of Rights and Preferences of Series A Convertible Preferred Stock*
4.1(b)		Certificate of Designation*
4.1(c)		Amendment to Certificate of Designation After Issuance of Class or Series dated 3/14/2014*
4.1(d)		Amendment to Certificate of Designation After Issuance of Class or Series dated 01/12/2018*
10.1		Convertible Promissory Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 5, 2021*
10.2		Convertible Redeemable Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 7, 2022 *
10.3		Letter Agreement Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated July 18, 2022 *
10.4		Letter Agreement between Groove Botanicals, Inc. and Kent Rodriguez, CEO
21.1		List of Subsidiaries
31		Certification of the Chief Executive and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32		Certification of the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

Table of Contents

101		The following financial statements from the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders’ Equity (Deficit), (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
Exhibit Number		Exhibit Description
101.INS		INLINE XBRL INSTANCE DOCUMENT (THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT)
3.1(a)		Articles of Incorporation*
101.SCH		INLINE XBRL TAXONOMY EXTENSION SCHEMA
3.1(b)		Articles of Merger*
101.CAL		INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
3.1(c)		Agreement and Plan of Merger*
101.DEF		INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
3.1(d)		Amended Articles of Incorporation*
101.LAB		INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE
3.1(e)		Amended and Restated Certificate of Incorporation of the Registrant*
101.PRE		INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
3.2		Bylaws of the Registrant*
104		COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)
4.1(a)		Certificate of Designation of Series and Determination of Rights and Preferences of Series A Convertible Preferred Stock*
4.1(b)		Certificate of Designation*
4.1(c)		Amendment to Certificate of Designation After Issuance of Class or Series dated 3/14/2014*
4.1(d)		Amendment to Certificate of Designation After Issuance of Class or Series dated 01/12/2018*
10.1		Convertible Promissory Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 5, 2021*
10.2		Convertible Redeemable Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 7, 2022 *
10.3		Letter Agreement Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated July 18, 2022 *
10.4		Letter Agreement between Groove Botanicals, Inc. and Kent Rodriguez, CEO*
21.1		List of Subsidiaries*
31		Certification of the Chief Executive and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32		Certification of the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

101		The following financial statements from the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders’ Equity (Deficit), (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
101.INS		INLINE XBRL INSTANCE DOCUMENT (THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT)
101.SCH		INLINE XBRL TAXONOMY EXTENSION SCHEMA
101.CAL		INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF		INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB		INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE		INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
104		COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)

________________

* Incorporated by reference to a previously filed exhibit or report.

Item 16. Form 10-K Summary

None.

28 34 Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

	GROOVE BOTANICALS INC.
Date: July 15, 2025	By:	/s/ Kent Rodriguez
Date: June 29, 2026	By:	/s/ Kent Rodriguez
		Kent Rodriguez
		President, Secretary, Treasurer and Director
		(Principal Executive Officer)
		(Principal Financial and Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual report on Form 10-K is signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Kent Rodriguez	President, Secretary, Treasurer and Director	~~July~~June 1529, ~~2025~~2026
Kent Rodriguez	(Principal Executive Officer)
	(Principal Financial and Accounting Officer)

29 35

Filing Compare · GROOVE BOTANICALS INC.